Cadrenal Therapeutics (CVKD) Competitors

$5.05 -0.22 (-4.17%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$5.10 +0.04 (+0.89%)

As of 05/15/2026 07:42 PM Eastern

CVKD vs. BYSI, FLNA, HYFT, CING, and IZTC

Should you buy Cadrenal Therapeutics stock or one of its competitors? MarketBeat compares Cadrenal Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadrenal Therapeutics include BeyondSpring (BYSI), Cassava Sciences (FLNA), MindWalk (HYFT), Cingulate (CING), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.

How does Cadrenal Therapeutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

BeyondSpring has higher revenue and earnings than Cadrenal Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	31.96	-$1.01M	-$0.15	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 157.43%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BeyondSpring has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

In the previous week, BeyondSpring had 3 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 5 mentions for BeyondSpring and 2 mentions for Cadrenal Therapeutics. BeyondSpring's average media sentiment score of 0.96 beat Cadrenal Therapeutics' score of 0.87 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Positive
Cadrenal Therapeutics	Positive

BeyondSpring's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Summary

BeyondSpring beats Cadrenal Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Cassava Sciences?

Cadrenal Therapeutics (NASDAQ:CVKD) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Cassava Sciences' return on equity of -53.90% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Cassava Sciences	N/A	-53.90%	-34.20%

Cadrenal Therapeutics currently has a consensus target price of $13.00, indicating a potential upside of 157.43%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cadrenal Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

In the previous week, Cadrenal Therapeutics and Cadrenal Therapeutics both had 2 articles in the media. Cassava Sciences' average media sentiment score of 1.61 beat Cadrenal Therapeutics' score of 0.87 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Cassava Sciences	Very Positive

Summary

Cadrenal Therapeutics and Cassava Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

MindWalk presently has a consensus price target of $5.00, indicating a potential upside of 320.17%. Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 157.43%. Given MindWalk's stronger consensus rating and higher possible upside, equities research analysts plainly believe MindWalk is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics has lower revenue, but higher earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.12	-$21.69M	-$0.20	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, MindWalk and MindWalk both had 2 articles in the media. MindWalk's average media sentiment score of 0.93 beat Cadrenal Therapeutics' score of 0.87 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Positive
Cadrenal Therapeutics	Positive

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MindWalk has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Cadrenal Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Summary

MindWalk beats Cadrenal Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Cingulate currently has a consensus target price of $34.50, indicating a potential upside of 654.92%. Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 157.43%. Given Cingulate's stronger consensus rating and higher probable upside, equities analysts clearly believe Cingulate is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics' return on equity of -411.03% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-723.31%	-212.87%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cingulate had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for Cingulate and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.87 beat Cingulate's score of -0.37 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Cadrenal Therapeutics	Positive

Cingulate has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Cingulate is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Summary

Cingulate beats Cadrenal Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 157.43%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Invizyne Technologies' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for Invizyne Technologies. Cadrenal Therapeutics' average media sentiment score of 0.87 beat Invizyne Technologies' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Cadrenal Therapeutics	Positive

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cadrenal Therapeutics beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.12M	$3.39B	$6.33B	$12.47B
Dividend Yield	N/A	2.31%	2.80%	5.28%
P/E Ratio	-0.90	18.03	20.29	25.23
Price / Sales	N/A	284.83	548.26	83.32
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	8.02	6.63	9.83	6.91
Net Income	-$13.24M	$24.40M	$3.56B	$334.11M
7 Day Performance	-17.08%	3.88%	0.25%	0.01%
1 Month Performance	4.12%	-2.84%	-1.30%	1.17%
1 Year Performance	-67.42%	62.79%	33.61%	30.68%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.775 of 5 stars	$5.05 -4.2%	$13.00 +157.4%	-66.6%	$15.12M	N/A	N/A	4	Analyst Revision Gap Down
BYSI BeyondSpring	0.2597 of 5 stars	$1.39 -8.6%	N/A	-19.0%	$62.50M	$1.75M	N/A	80	Earnings Report
FLNA Cassava Sciences	0.4141 of 5 stars	$1.20 -6.3%	N/A	-42.4%	$61.83M	N/A	N/A	20	Positive News
HYFT MindWalk	2.9914 of 5 stars	$1.28 -3.0%	$5.00 +290.6%	N/A	$60.93M	$17.59M	N/A	80
CING Cingulate	2.205 of 5 stars	$4.79 -3.4%	$34.50 +620.3%	+18.1%	$60.77M	N/A	N/A	20	News Coverage Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. BYSI, FLNA, HYFT, CING, and IZTC

How does Cadrenal Therapeutics compare to BeyondSpring?

Summary

How does Cadrenal Therapeutics compare to Cassava Sciences?

Summary

How does Cadrenal Therapeutics compare to MindWalk?

Summary

How does Cadrenal Therapeutics compare to Cingulate?

Summary

How does Cadrenal Therapeutics compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. BYSI, FLNA, HYFT, CING, and IZTC

How does Cadrenal Therapeutics compare to BeyondSpring?

Which has higher valuation and earnings, BYSI or CVKD?

Do analysts recommend BYSI or CVKD?

Do insiders and institutionals hold more shares of BYSI or CVKD?

Which has more volatility and risk, BYSI or CVKD?

Does the media prefer BYSI or CVKD?

Is BYSI or CVKD more profitable?

Summary

How does Cadrenal Therapeutics compare to Cassava Sciences?

Is CVKD or FLNA more profitable?

Do analysts rate CVKD or FLNA?

Which has higher earnings & valuation, CVKD or FLNA?

Do insiders & institutionals hold more shares of CVKD or FLNA?

Which has more volatility & risk, CVKD or FLNA?

Does the media refer more to CVKD or FLNA?

Summary

How does Cadrenal Therapeutics compare to MindWalk?

Do analysts prefer HYFT or CVKD?

Which has preferable earnings & valuation, HYFT or CVKD?

Does the media refer more to HYFT or CVKD?

Do insiders & institutionals hold more shares of HYFT or CVKD?

Which has more risk and volatility, HYFT or CVKD?

Is HYFT or CVKD more profitable?

Summary

How does Cadrenal Therapeutics compare to Cingulate?

Do analysts recommend CING or CVKD?

Is CING or CVKD more profitable?

Do insiders and institutionals believe in CING or CVKD?

Does the media refer more to CING or CVKD?

Which has more volatility and risk, CING or CVKD?

Which has stronger earnings & valuation, CING or CVKD?

Summary

How does Cadrenal Therapeutics compare to Invizyne Technologies?

Do analysts recommend IZTC or CVKD?

Is IZTC or CVKD more profitable?

Which has stronger earnings and valuation, IZTC or CVKD?

Does the media prefer IZTC or CVKD?

Do institutionals and insiders have more ownership in IZTC or CVKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools